> Switzerland's Piqur Therapeutics just raised $19 million for its cancer drug R&D specializing in PI3K and mTOR inhibition. The biotech has raised a total of $60 million and is pushing its lead therapy, PQR309, through mid-stage tests. Versant Ventures joined a syndicate behind the A2 round. Release